Premium
Functionalized Biomimetic Magnetic Nanoparticles as Effective Nanocarriers for Targeted Chemotherapy
Author(s) -
Peigneux Ana,
Oltolina Francesca,
Colangelo Donato,
Iglesias Guillermo R.,
Delgado Angel V.,
Prat Maria,
JimenezLopez Concepcion
Publication year - 2019
Publication title -
particle and particle systems characterization
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.877
H-Index - 56
eISSN - 1521-4117
pISSN - 0934-0866
DOI - 10.1002/ppsc.201900057
Subject(s) - nanocarriers , doxorubicin , monoclonal antibody , in vivo , cytotoxicity , magnetic hyperthermia , nanoparticle , hyperthermia , materials science , biophysics , nanotechnology , cancer research , chemistry , magnetic nanoparticles , in vitro , chemotherapy , antibody , biochemistry , medicine , biology , immunology , microbiology and biotechnology , surgery
Novel MamC‐mediated biomimetic magnetic nanoparticles (BMNPs) are proposed as valuable carriers for targeted chemotherapy because of the size (36 ± 12 nm) and of surface properties conferred by MamC coating. They are super‐paramagnetic at room and body temperatures, have a large magnetic moment per particle, mediate hyperthermia, are cytocompatible, and, having a negative surface charge at physiological pH, can be efficiently coupled with DOXOrubicin (DOXO) and a monoclonal antibody (mAb) directed against the human Met/hepatocyte growth factor receptor (overexpressed in many cancers) displaying coupling stability, while releasing DOXO at acidic pH. This release can be enhanced by hyperthermia. The DOXO‐mAb‐BMNPs selectively recognize Met, bind efficiently to Met + tumor cells, and discharge DOXO within their nuclei more efficiently than DOXO‐BMNPs, exerting cytotoxicity. These data represent proof of concept for future in vivo experiments in which the controlled dual targeting (mAb‐mediated and magnetic) approach and combined (chemotherapy and hyperthermia) therapy will be studied.